If you missed the early fall push for flu and COVID-19 vaccines, it's not too late. Health officials say it's important to ...

Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

Targeted therapy revolutionized cancer treatment, with gene fusions leading the way when the FDA approved imatinib in 2001 to ...

MODERNA reported a surprise third-quarter profit on Thursday (Nov 7), driven by cost cutting and higher-than-expected sales ...

If you're looking for an undervalued growth stock to buy right now, Pfizer (NYSE: PFE) is an investment that should be near ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

One stock yields 6% today. Another has grown its dividend by 460% over the past decade. Both are blue chip bargains to buy ...

They found that mRNA vaccines that target C. diff cells and the toxins they produce generated a lasting immune response in mice and hamsters.

An influx of late-phase programs has prompted Genmab to reassess its bets. | An influx of late-phase programs has prompted Genmab to reassess its bets. The biotech is axing three early-stage clinical ...

Androgenetic alopecia (AGA) is the leading cause of hair loss in both men and women. Experts outline current and emerging therapies in ...

Genmab reported impressive earnings with significant revenue growth driven by its key products, despite rising expenses.